膀胱がん(Bladder Cancer):治療薬開発パイプライン動向(2016年下半期版)

Global Markets Directが発行した調査報告書(DATA70209356)
◆英語タイトル:Bladder Cancer - Pipeline Review, H2 2016
◆商品コード:DATA70209356
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2016年11月9日
◆ページ数:742
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における膀胱がん(Bladder Cancer)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・膀胱がん(Bladder Cancer)の概要
・膀胱がん(Bladder Cancer)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・膀胱がん(Bladder Cancer)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・膀胱がん(Bladder Cancer)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・膀胱がん(Bladder Cancer)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Bladder Cancer – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer – Pipeline Review, H2 2016, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 44, 35, 2, 56 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 12 and 2 molecules, respectively.Bladder Cancer.

Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 7
Bladder Cancer Overview 8
Therapeutics Development 9
Bladder Cancer – Therapeutics under Development by Companies 11
Bladder Cancer – Therapeutics under Investigation by Universities/Institutes 19
Bladder Cancer – Pipeline Products Glance 20
Bladder Cancer – Products under Development by Companies 23
Bladder Cancer – Products under Investigation by Universities/Institutes 34
Bladder Cancer – Companies Involved in Therapeutics Development 35
Bladder Cancer – Therapeutics Assessment 144
Drug Profiles 167
Bladder Cancer – Dormant Projects 693
Bladder Cancer – Discontinued Products 703
Bladder Cancer – Product Development Milestones 704
Appendix 721

List of Tables
Number of Products under Development for Bladder Cancer, H2 2016 29
Number of Products under Development for Bladder Cancer - Comparative Analysis, H2 2016 30
Number of Products under Development by Companies, H2 2016 31
Number of Products under Development by Companies, H2 2016 (Contd..1) 32
Number of Products under Development by Companies, H2 2016 (Contd..2) 33
Number of Products under Development by Companies, H2 2016 (Contd..3) 34
Number of Products under Development by Companies, H2 2016 (Contd..4) 35
Number of Products under Development by Companies, H2 2016 (Contd..5) 36
Number of Products under Development by Companies, H2 2016 (Contd..6) 37
Number of Products under Development by Companies, H2 2016 (Contd..7) 38
Number of Products under Investigation by Universities/Institutes, H2 2016 39
Comparative Analysis by Late Stage Development, H2 2016 40
Comparative Analysis by Clinical Stage Development, H2 2016 41
Comparative Analysis by Early Stage Development, H2 2016 42
Products under Development by Companies, H2 2016 43
Products under Development by Companies, H2 2016 (Contd..1) 44
Products under Development by Companies, H2 2016 (Contd..2) 45
Products under Development by Companies, H2 2016 (Contd..3) 46
Products under Development by Companies, H2 2016 (Contd..4) 47
Products under Development by Companies, H2 2016 (Contd..5) 48
Products under Development by Companies, H2 2016 (Contd..6) 49
Products under Development by Companies, H2 2016 (Contd..7) 50
Products under Development by Companies, H2 2016 (Contd..8) 51
Products under Development by Companies, H2 2016 (Contd..9) 52
Products under Development by Companies, H2 2016 (Contd..10) 53
Products under Investigation by Universities/Institutes, H2 2016 54
Bladder Cancer - Pipeline by 4SC AG, H2 2016 55
Bladder Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 56
Bladder Cancer - Pipeline by ADC Therapeutics SA, H2 2016 57
Bladder Cancer - Pipeline by Agenus Inc, H2 2016 58
Bladder Cancer - Pipeline by Altor BioScience Corporation, H2 2016 59
Bladder Cancer - Pipeline by AndroScience Corporation, H2 2016 60
Bladder Cancer - Pipeline by APIM Therapeutics AS, H2 2016 61
Bladder Cancer - Pipeline by Arno Therapeutics, Inc., H2 2016 62
Bladder Cancer - Pipeline by Astellas Pharma Inc., H2 2016 63
Bladder Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 64
Bladder Cancer - Pipeline by Aura Biosciences, Inc., H2 2016 65
Bladder Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 66
Bladder Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2016 67
Bladder Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 68
Bladder Cancer - Pipeline by Bayer AG, H2 2016 69
Bladder Cancer - Pipeline by BioCancell Ltd, H2 2016 70
Bladder Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H2 2016 71
Bladder Cancer - Pipeline by Bioncotech Therapeutics SL, H2 2016 72
Bladder Cancer - Pipeline by Biotest AG, H2 2016 73
Bladder Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 74
Bladder Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 75
Bladder Cancer - Pipeline by Celgene Corporation, H2 2016 76
Bladder Cancer - Pipeline by Cellceutix Corporation, H2 2016 77
Bladder Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016 78
Bladder Cancer - Pipeline by Celprogen, Inc., H2 2016 79
Bladder Cancer - Pipeline by Celsion Corporation, H2 2016 80
Bladder Cancer - Pipeline by Codagenix, Inc., H2 2016 81
Bladder Cancer - Pipeline by Cold Genesys, Inc., H2 2016 82
Bladder Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016 83
Bladder Cancer - Pipeline by CytomX Therapeutics, Inc., H2 2016 84
Bladder Cancer - Pipeline by DormaTarg, Inc., H2 2016 85
Bladder Cancer - Pipeline by Eisai Co., Ltd., H2 2016 86
Bladder Cancer - Pipeline by Eleven Biotherapeutics Inc., H2 2016 87
Bladder Cancer - Pipeline by Eli Lilly and Company, H2 2016 88
Bladder Cancer - Pipeline by Elsalys Biotech SAS, H2 2016 89
Bladder Cancer - Pipeline by enGene, Inc, H2 2016 90
ancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2016 91
Bladder Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 93
Bladder Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2016 94
Bladder Cancer - Pipeline by Gene Signal International SA, H2 2016 95
Bladder Cancer - Pipeline by Genmab A/S, H2 2016 96
Bladder Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 97
Bladder Cancer - Pipeline by H3 Biomedicine Inc., H2 2016 98
Bladder Cancer - Pipeline by Hamlet Pharma AB, H2 2016 99
Bladder Cancer - Pipeline by Heat Biologics, Inc., H2 2016 100
Bladder Cancer - Pipeline by HEC Pharm Co., Ltd., H2 2016 101
Bladder Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016 102
Bladder Cancer - Pipeline by Idera Pharmaceuticals, Inc., H2 2016 103
Bladder Cancer - Pipeline by ImmuNext, Inc., H2 2016 104
Bladder Cancer - Pipeline by Immunocore Limited, H2 2016 105
Bladder Cancer - Pipeline by Immunomedics, Inc., H2 2016 106
Bladder Cancer - Pipeline by Immupharma Plc, H2 2016 107
Bladder Cancer - Pipeline by InteRNA Technologies B.V., H2 2016 108
Bladder Cancer - Pipeline by Johnson & Johnson, H2 2016 109
Bladder Cancer - Pipeline by LipoMedix Pharmaceutical Inc., H2 2016 110
Bladder Cancer - Pipeline by MacroGenics, Inc., H2 2016 111
Bladder Cancer - Pipeline by MaxiVAX SA, H2 2016 112
Bladder Cancer - Pipeline by Meabco A/S, H2 2016 113
Bladder Cancer - Pipeline by Medicenna Therapeutics, Inc., H2 2016 114
Bladder Cancer - Pipeline by MedImmune LLC, H2 2016 115
Bladder Cancer - Pipeline by Merck & Co., Inc., H2 2016 116
Bladder Cancer - Pipeline by Merck KGaA, H2 2016 117
Bladder Cancer - Pipeline by Mirati Therapeutics Inc., H2 2016 118
Bladder Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2016 119
Bladder Cancer - Pipeline by Miyarisan Pharmaceutical Company, Ltd, H2 2016 120
Bladder Cancer - Pipeline by Moleculin Biotech Inc, H2 2016 121
Bladder Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2016 122
Bladder Cancer - Pipeline by Nektar Therapeutics, H2 2016 123
Bladder Cancer - Pipeline by NuCana BioMed Limited, H2 2016 124
Bladder Cancer - Pipeline by Omeros Corporation, H2 2016 125
Bladder Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2016 126
Bladder Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016 127
Bladder Cancer - Pipeline by OncoTherapy Science, Inc., H2 2016 128
Bladder Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 129
Bladder Cancer - Pipeline by Optimum Therapeutics, LLC, H2 2016 130
Bladder Cancer - Pipeline by Pfizer Inc., H2 2016 131
Bladder Cancer - Pipeline by Pharma Mar, S.A., H2 2016 132
Bladder Cancer - Pipeline by Philogen S.p.A., H2 2016 133
Bladder Cancer - Pipeline by Plexxikon Inc., H2 2016 134
Bladder Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016 135
Bladder Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016 136
Bladder Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2016 137
Bladder Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016 138
Bladder Cancer - Pipeline by Rodos BioTarget GmbH, H2 2016 139
Bladder Cancer - Pipeline by Sanofi, H2 2016 140
Bladder Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016 141
Bladder Cancer - Pipeline by Serometrix, LLC, H2 2016 142
Bladder Cancer - Pipeline by Shionogi & Co., Ltd., H2 2016 143
Bladder Cancer - Pipeline by Sillajen Biotherapeutics, H2 2016 144
Bladder Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2016 145
Bladder Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 146
Bladder Cancer - Pipeline by Stemline Therapeutics, Inc., H2 2016 147
Bladder Cancer - Pipeline by Sun Pharma Advanced Research Co Ltd, H2 2016 148
Bladder Cancer - Pipeline by Synovo GmbH, H2 2016 149
Bladder Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 150
Bladder Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 151
Bladder Cancer - Pipeline by Taris Biomedical LLC, H2 2016 152
Bladder Cancer - Pipeline by Telormedix SA, H2 2016 153
Bladder Cancer - Pipeline by TesoRx Pharma LLC, H2 2016 154
Bladder Cancer - Pipeline by Theravectys SA, H2 2016 155
Bladder Cancer - Pipeline by Theryte Limited, H2 2016 156
Bladder Cancer - Pipeline by Transgene SA, H2 2016 157
Bladder Cancer - Pipeline by UroGen Pharmaceuticals, Ltd., H2 2016 158
Bladder Cancer - Pipeline by Vakzine Projekt Management GmbH, H2 2016 159
Bladder Cancer - Pipeline by Vault Pharma Inc., H2 2016 160
Bladder Cancer - Pipeline by Vaxeal Holding SA, H2 2016 161
Bladder Cancer - Pipeline by Vaxiion Therapeutics, Inc., H2 2016 162
Bladder Cancer - Pipeline by Viralytics Ltd., H2 2016 163
Assessment by Monotherapy Products, H2 2016 164
Assessment by Combination Products, H2 2016 165
Number of Products by Stage and Target, H2 2016 167
Number of Products by Stage and Mechanism of Action, H2 2016 175
Number of Products by Stage and Route of Administration, H2 2016 184
Number of Products by Stage and Molecule Type, H2 2016 186
Bladder Cancer - Dormant Projects, H2 2016 713
Bladder Cancer - Dormant Projects (Contd..1), H2 2016 714
Bladder Cancer - Dormant Projects (Contd..2), H2 2016 715
Bladder Cancer - Dormant Projects (Contd..3), H2 2016 716
Bladder Cancer - Dormant Projects (Contd..4), H2 2016 717
Bladder Cancer - Dormant Projects (Contd..5), H2 2016 718
Bladder Cancer - Dormant Projects (Contd..6), H2 2016 719
Bladder Cancer - Dormant Projects (Contd..7), H2 2016 720
Bladder Cancer - Dormant Projects (Contd..8), H2 2016 721
Bladder Cancer - Dormant Projects (Contd..9), H2 2016 722
Bladder Cancer - Discontinued Products, H2 2016 723

List of Figures
Number of Products under Development for Bladder Cancer, H2 2016 29
Number of Products under Development for Bladder Cancer - Comparative Analysis, H2 2016 30
Number of Products under Development by Companies, H2 2016 31
Number of Products under Investigation by Universities/Institutes, H2 2016 39
Comparative Analysis by Late Stage Development, H2 2016 40
Comparative Analysis by Clinical Stage Development, H2 2016 41
Comparative Analysis by Early Stage Products, H2 2016 42
Assessment by Monotherapy Products, H2 2016 164
Assessment by Combination Products, H2 2016 165
Number of Products by Top 10 Targets, H2 2016 166
Number of Products by Stage and Top 10 Targets, H2 2016 166
Number of Products by Top 10 Mechanism of Actions, H2 2016 174
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 174
Number of Products by Top 10 Routes of Administration, H2 2016 183
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 183
Number of Products by Top 10 Molecule Types, H2 2016 185
Number of Products by Stage and Top 10 Molecule Types, H2 2016 185

【レポートのキーワード】

膀胱がん(Bladder Cancer)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 膀胱がん(Bladder Cancer):治療薬開発パイプライン動向(2016年下半期版)(Bladder Cancer - Pipeline Review, H2 2016)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆